Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.

[1]  J. Jeekel,et al.  Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I-II trial. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  A. Eggermont,et al.  Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  F. Fiore,et al.  Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  H. Wanebo,et al.  Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[5]  T. Wiggers,et al.  Surgery for locally recurrent rectal cancer , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[6]  H. Wanebo,et al.  Neoadjuvant therapy with high dose chemotherapy via isolated pelvic intra-abdominal perfusion with bone marrow stem cell support for advanced endometrial cancer. , 2003, Medicine and health, Rhode Island.

[7]  M. Valenti,et al.  Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study , 2003, Melanoma research.

[8]  O. Martinet,et al.  Isolated liver perfusion for non-resectable liver tumours: a review. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  S. Mocellin,et al.  Stop-flow technique for loco-regional delivery of antiblastic agents: literature review and personal experience. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  J. Hofland,et al.  Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy. , 2002, British journal of anaesthesia.

[11]  M. Valenti,et al.  Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. , 2002, American journal of surgery.

[12]  R. Hilger,et al.  Curative and palliative aspects of regional chemotherapy in combination with surgery , 2002, Supportive Care in Cancer.

[13]  S. Lucchi,et al.  Treatment of unresectable malignant abdominal, pelvic and thoracic tumors using abdominal pelvic and thoracic stop-flow chemotherapy. , 2001, Anticancer research.

[14]  S. Libutti,et al.  Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. , 2001, Surgery.

[15]  M. Valenti,et al.  Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer. , 2001, Archives of surgery.

[16]  M. Kornmann,et al.  Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  L. Rutqvist,et al.  Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm , 2000, The Lancet.

[18]  K. Havenga,et al.  Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  G. Sgourakis,et al.  Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. , 1999, Hepato-gastroenterology.

[20]  H. Wanebo,et al.  A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion , 1999, Cancer Chemotherapy and Pharmacology.

[21]  S. Houry,et al.  Treatment of local recurrence of rectal cancer. , 1998, American journal of surgery.

[22]  C. V. D. van de Velde,et al.  Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  A. Eggermont,et al.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. , 1998, Annals of surgery.

[24]  A. Eggermont,et al.  Determination of melphalan and hydrolysis products in body fluids by GC-MS , 1997 .

[25]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[26]  T. Wiggers,et al.  Surgery for local recurrence of rectal carcinoma , 1996, Diseases of the colon and rectum.

[27]  P. Sagar,et al.  Surgical management of locally recurrent rectal cancer , 1996, The British journal of surgery.

[28]  R. Aitken,et al.  Mesorectal excision for rectal cancer , 1996, The British journal of surgery.

[29]  M. Papa,et al.  Vascular complications of total abdominal perfusion and aortic stop‐flow infusion , 1996, Journal of surgical oncology.

[30]  F. Shamsa,et al.  Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C. , 1995, The Journal of surgical research.

[31]  N. Saunders.  Pelvic exenteration: by whom and for whom? , 1995, The Lancet.

[32]  H. Wanebo,et al.  Pelvic resection of recurrent rectal cancer , 1994, Annals of surgery.

[33]  L. Rutqvist,et al.  Local recurrence of rectal adenocarcinoma after ‘curative’ surgery with and without preoperative radiotherapy , 1994, The British journal of surgery.

[34]  P. Kam,et al.  A percutaneous aortic stop-flow infusion technique for regional cytotoxic therapy of the abdomen and pelvis , 1994 .

[35]  K. Aigner.  Regional chemotherapy: editorial review article , 1994 .

[36]  K. Aigner,et al.  Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer , 1994 .

[37]  H. Wanebo,et al.  Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. , 1993, Archives of surgery.

[38]  J. Macfarlane,et al.  Mesorectal excision for rectal cancer , 1993, The Lancet.

[39]  M. Mohiuddin,et al.  Patterns of recurrence following high-dose preoperative radiation and sphincter-preserving surgery for cancer of the rectum , 1993, Diseases of the colon and rectum.

[40]  C. V. D. van de Velde,et al.  Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. , 1991, Cancer research.

[41]  U. Tjaden,et al.  Chromatographic analysis of anticancer drugs. , 1990, Journal of chromatography.

[42]  L. Vannucci,et al.  Local recurrence after curative resection of colorectal adenocarcinoma. , 1990, Surgery.

[43]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[44]  H. Schuitemaker,et al.  cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. , 1988, Cancer research.

[45]  P. Kuppen,et al.  Variations in exposure to mitomycin C in an in vitro colony-forming assay. , 1986, British Journal of Cancer.

[46]  B. Teicher,et al.  Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. , 1981, Cancer research.

[47]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[48]  R. Heald.  A new approach to rectal cancer. , 1979, British journal of hospital medicine.